Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar details
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- The Discovery of Protein Phosphorylation
-
45 min
1. Phosphorylase and the origin of reversible protein phosphorylation- Prof. Edmond Fischer
-
21 min
- Protein Kinase Cascades
-
32 min
- The Modulation of Protein Function by Phosphorylation
-
33 min
4. Two is the key to 14-3-3: dimeric mechanical signaling devices- Prof. Carol MacKintosh
- Protein Phosphatases
-
38 min
5. Structure and mechanisms of protein phosphatases- Prof. David Barford
-
45 min
6. Protein tyrosine phosphatases- Prof. Jack Dixon
-
49 min
7. The regulation of MAP kinase signalling by dual-specificity protein phosphatases- Prof. Steve M. Keyse
-
22 min
- The Structures of Protein Kinases
-
45 min
9. Protein kinase structure, function and regulation- Prof. Susan Taylor
-
42 min
10. The structural basis for the modulation of protein function by protein phosphorylation- Prof. Dame Louise N. Johnson
- Biological Systems that are Regulated by Reversible Phosphorylation
-
50 min
11. Protein phosphorylation and the control of protein synthesis- Prof. Christopher Proud
-
62 min
-
40 min
13. Roles of AMPK in energy homeostasis and nutrient sensing- Prof. Grahame Hardie
-
56 min
14. Serine kinases and T lymphocyte biology- Prof. Doreen Cantrell
-
30 min
15. The interplay between protein phosphorylation and ubiquitylation in the NF-κB pathway- Prof. Zhijian 'James' Chen
-
58 min
16. SMAD phosphorylation and the TGF-beta pathway- Prof. Joan Massagué
- Protein Kinases and Human Disease
-
58 min
17. Function and regulation of the PDK1 kinase- Prof. Dario Alessi
-
63 min
18. LKB1 pathway and its role in cancer- Prof. Dario Alessi
-
51 min
19. WNK1 pathway and its role in regulating hypertension- Prof. Dario Alessi
-
33 min
20. The hyperphosphorylation of tau and Alzheimer's disease- Prof. Michel Goedert
- Protein Kinases as Targets for the Development of Anti-Cancer Drugs
-
68 min
21. PI3K/AKT signaling in cancer- Prof. Neal Rosen
-
37 min
22. RAS and RAF signaling in melanoma: biology and therapies- Prof. Richard Marais
-
38 min
23. The mTOR kinase as a target for anti-cancer drugs- Prof. David Sabatini
- Archived Lectures *These may not cover the latest advances in the field
-
51 min
-
38 min
25. AMP-activated protein kinase: regulating cellular and whole body energy balance- Prof. Grahame Hardie
Printable Handouts
Navigable Slide Index
- Introduction
- Acknowledgements
- T cell development and function
- T cell activation
- From nave to activated cytotoxic T cells (1)
- Immune activation regulates different processes
- From nave to activated cytotoxic T cells (2)
- Primary T cells express approx. 24,566 genes
- The key question
- The immunological synapse
- T cell activation: lots of receptors
- Our focus is the serine kinase networks
- The human kinome
- How complex is the T cell phosphoproteome?
- Identification of serine threonine phosphorylations
- Kinases predicted to be active in CTL (1)
- Functions of the CTL phosphoproteins
- Serine/ threonine kinases in T cell biology
- Kinases predicted to be active in CTL (2)
- PKB signal transduction
- Tools to probe PI3K/PDK1/PKB's role in CTL
- Inhibitors prevent phosphorylation of PKB in CTL
- AktI 1/2 blocks phosphorylation and activity of PKB
- Deletion of PDK1 blocks PKB/Akt activation
- What is the role of PKB/Akt in CTL?
- CTL express approximately 9405 genes
- Inhibition of PKB and decrease in cytolytic effectors
- Inhibition of PKB and downregulation of perforin
- PKB determines repertoire of cytokine receptors
- PKB increases expression of CD62L and CCR7
- What are CCR7 and CD62L?
- Primary naive T cells
- CD62L and CCR7 direct lymphocyte transmigration
- CTL lose expression of CCR7 and CD62L
- CD62L and CCR7 in naive/ memory and CD8 T cells
- CD62L and CCR7 mRNA expression
- PKB inhibition restores CD62L and CCR7
- Can PKB inhibition reprogram T cell trafficking?
- In vivo homing experiments
- CTL treated with PKB inhibitor regain homing ability
- Will PIP3 & PKB activation switch off CCR7,CD62L?
- How to get increased PIP3 and PKB activation
- PTEN deletions/downregulation occur in tumours
- Producing CTL that lack both PTEN and PDK1
- PTEN deletion stimulates PKB activity via PDK1
- PTEN deletion de-regulates adhesion, chemokines
- PTEN-null T cells don't home to lymphoid organs
- PKB required to switch off CD62L & CCR7
- PKB phosphorylates Foxo1 and Foxo3A
- Does non phosphorylatable Foxo restore CD62L?
- Phosphorylated Foxo restores CD62L expression
- How does Foxo control CD62L & CCR7 expression
- PKB activity down-regulates KLF2 mRNA (1)
- PKB activity down-regulates KLF2 mRNA (2)
- Inhibition of PI3K or PKB restores KLF2 expression
- Re-expression of KLF2 in CTL upregulates CD62L
- PKB cascade and KLF2
- PKB controls T cell trafficking via Foxo
- Summary of nave vs. cytotoxic cells
- Serine kinase are important in T cells
- Many more genes to work on
Topics Covered
- T cell development and function
- T cell activation
- Serine kinase networks
- T cell phosphoproteome
- Kinases active in CTL
- Functions of the CTL phosphoproteins
- PKB signal transduction
- PKB/Akt role in CTL
- Inhibition of PKB
- CCR7 and CD62L
- Homing ability in CTL
- PIP3 & PKB activation
- PTEN deletion/down-regulation effect
- PKB phosphorylates Foxo1 and Foxo3A
- Foxo and CD62L & CCR7 expression
- PKB cascade and KLF2
- PKB controls T cell trafficking via Foxo
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Cantrell, D. (2011, August 15). Serine kinases and T lymphocyte biology [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved January 15, 2025, from https://doi.org/10.69645/ZHFM5960.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Doreen Cantrell has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Serine kinases and T lymphocyte biology
Published on August 15, 2011
56 min
